Innovator’s Pitch Challenge

Vote for Us

Interested in Connecting? Please contact:
Michael Bruckman
CEO
mbruckman@haimatherapeutics.com

Message the company or request a 1:1 meeting here

Haima Therapeutics is a pre-clinical stage biotechnology company focused on the development of platelet-inspired therapeutics to control bleeding and treat other blood-related disorders where platelets play a key role in its progression, such as thrombosis, inflammation, cancer metastasis and other pathologies. Platelets are anuclear cells that circulate in the blood and touch every organ system in the body; and are considered nature’s delivery vehicles. Their primary role is to stop bleeding (hemostasis), but platelets drive many other physio/pathological conditions in the body including thrombosis, inflammation, cancer, and neurodegeneration. Haima’s lead product, SynthoPlateTM, is a hemostatic technology that mitigates bleeding by amplifying and accelerating the body’s natural clotting mechanisms.

Pitch Video

Slide Deck